Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 13/20 | 0.77 |
| ▸ | CDK2 | P24941 | 4/20 | 0.65 |
| ▸ | CDK1 | P06493 | 2/20 | 0.61 |
| ▸ | CDK4 | P11802 | 1/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521888 | 0.94 | IKBKB (0.78) | IKBKBCDK2CDK1CDK4MAPK8 | |
| SCHEMBL3521241 | 0.91 | IKBKB (0.74) | IKBKBCDK2CDK1CDK4MAPK8 | |
| SCHEMBL3520093 | 0.90 | IKBKB (0.72) | IKBKBCDK2CDK1CDK4MAPK8 | |
| SCHEMBL3516492 | 0.90 | IKBKB (0.72) | IKBKBCDK2CDK1CDK4MAPK8 | |
| SCHEMBL3522686 | 0.90 | IKBKB (0.72) | IKBKBCDK2CDK1CDK4MAPK8 | |
| SCHEMBL3516668 | 0.88 | IKBKB (0.68) | IKBKBCDK2CDK1CDK4MAPK8 | |
| SCHEMBL3522392 | 0.88 | IKBKB (0.70) | IKBKBCDK2CDK1CDK4CHUK | |
| SCHEMBL3516111 | 0.88 | IKBKB (0.70) | IKBKBCDK2CDK1CDK4MAPK8 | |
| SCHEMBL3518431 | 0.87 | IKBKB (1.00) | IKBKBCDK2CDK4MAPK8MAPK10 | |
| SCHEMBL3522127 | 0.87 | IKBKB (0.69) | IKBKBCDK2CDK1CDK4MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885CDK2 11/4885CDK1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.